Moderna’s COVID-19 vaccine generates twice as many antibodies as Pfizer’s vaccine, a Belgian study has claimed.
The study got recently published in the Journal of the American Medical Association (JAMA) and involved a direct comparison of individual immune responses of over 2,500 healthcare workers who hadn’t contracted COVID-19 before.
According to details, on average, the antibody levels among the recipients of the two-dose Moderna’s vaccine were 2,881 units/mL in comparison to the 1,108 units/mL among the recipients of the two-dose Pfizer’s vaccine.
The study has given two reasons for the massive difference in the number of antibodies generated by the two mRNA-based COVID-19 vaccines.
First, Moderna’s vaccine contains a higher amount of active ingredients than Pfizer. The former contains 100 micrograms of active ingredients while the latter contains only 30 micrograms of active ingredients.
Second, the interval between the two doses of Moderna’s vaccine is longer than Pfizer. The former’s two doses are administered four weeks apart while the latter’s two doses are administered three weeks apart.
Earlier this month, an American study found that Moderna’s vaccine reduces the risk against SARS-COV-2 by twice as much as Pfizer’s vaccine.